ABSI
Absci Corporation
Price Chart
Latest Quote
$8.23
-1.53 (-15.68%)
Current Price
| Previous Close | $9.76 |
| Open | $9.47 |
| Day High | $9.61 |
| Day Low | $8.10 |
| Volume | 7,411,240 |
Stock Information
| Shares Outstanding | 169.40M |
| Total Debt | $4.42M |
| Cash Equivalents | $125.70M |
| Revenue | $1.84M |
| Net Income | $-118.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.41B |
| EPS (TTM) | $-0.82 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.17B |
| Sales | $1.84M |
| Income | $-118.44M |
| Book/sh | $1.11 |
| Cash/sh | $0.74 |
| Employees | 140 |
Financial Ratios
| Quick Ratio | 6.28 |
| Current Ratio | 6.59 |
| Debt/Eq | 2.57 |
Returns & Margins
| ROA | -37.33% |
| ROE | -63.89% |
| Operating Margin | -14346.98% |
Ownership
| Insider Ownership | 12.04% |
| Institutional Ownership | 73.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.32 |
| P/S | 765.35 |
| P/B | 7.49 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $13.78 |
Technical Indicators
| SMA20 | $10.14 |
| SMA50 | $7.65 |
| SMA200 | $4.44 |
| RSI | 28.10 |
| ATR | 0.8928 |
| Shares Float | 148.72M |
| Short Float | 26.61% |
| Short Ratio | 4.62 |
| Volatility | 2.33 |
| Rel Volume | 0.47 |
Performance History
| Week | -21.75% |
| Month | +18.50% |
| Quarter | +156.81% |
| 6 Months | +147.61% |
| YTD | +129.78% |
| Year | +202.74% |
| 3 Years | +341.22% |
| 10 Years | -61.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $8.30 | 3,717,200 |
| 2026-07-16 | $8.23 | 7,431,800 |
| 2026-07-15 | $9.76 | 3,438,600 |
| 2026-07-14 | $10.23 | 3,287,500 |
| 2026-07-13 | $10.21 | 2,925,500 |
| 2026-07-10 | $10.60 | 4,696,700 |
| 2026-07-09 | $11.47 | 4,970,900 |
| 2026-07-08 | $11.10 | 6,599,900 |
| 2026-07-07 | $11.33 | 4,153,900 |
| 2026-07-06 | $11.54 | 5,484,600 |
| 2026-07-02 | $11.62 | 5,261,200 |
| 2026-07-01 | $11.11 | 5,084,100 |
| 2026-06-30 | $11.59 | 5,820,100 |
| 2026-06-29 | $11.35 | 8,120,100 |
| 2026-06-26 | $10.89 | 13,453,400 |
| 2026-06-25 | $10.21 | 13,216,200 |
| 2026-06-24 | $10.07 | 38,227,100 |
| 2026-06-23 | $7.41 | 5,999,900 |
| 2026-06-22 | $8.40 | 8,370,900 |
| 2026-06-18 | $7.41 | 8,444,200 |
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
đ° Latest News
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Zacks âĸ 2026-07-17T14:42:00Z
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Zacks âĸ 2026-07-13T13:55:02Z
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Zacks âĸ 2026-07-02T16:00:04Z
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Benzinga âĸ 2026-06-27T10:01:25Z
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Pharmaceutical Technology âĸ 2026-06-26T10:27:16Z
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-06-26T08:06:54Z
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Zacks âĸ 2026-06-25T14:21:00Z
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-25T10:18:00Z
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today?
Stocktwits âĸ 2026-06-25T03:24:38Z
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
Stocktwits âĸ 2026-06-24T19:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,800,000 | $4,534,000 | $5,718,000 | $5,747,000 |
| Operating Revenue | $2,800,000 | $4,534,000 | $5,718,000 | $5,747,000 |
| Expenses | ||||
| Interest Expense | $209,000 | $565,000 | $1,010,000 | $972,000 |
| Total Expenses | $128,218,000 | $113,422,000 | $99,898,000 | $112,497,000 |
| Other Income Expense | $10,513,000 | $6,417,000 | $-15,276,000 | $2,357,000 |
| Other Non Operating Income Expenses | $5,412,000 | $6,417,000 | $6,059,000 | $2,357,000 |
| Net Non Operating Interest Income Expense | $-209,000 | $-565,000 | $-1,010,000 | $-972,000 |
| Interest Expense Non Operating | $209,000 | $565,000 | $1,010,000 | $972,000 |
| Operating Expense | $128,218,000 | $113,422,000 | $99,898,000 | $112,497,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Net Interest Income | $-209,000 | $-565,000 | $-1,010,000 | $-972,000 |
| Normalized Income | $-119,212,790 | $-103,106,000 | $-93,711,350 | $-104,904,000 |
| Net Income From Continuing And Discontinued Operation | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Total Operating Income As Reported | $-120,317,000 | $-108,888,000 | $-115,515,000 | $-106,750,000 |
| Net Income Common Stockholders | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Net Income | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Net Income Including Noncontrolling Interests | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Net Income Continuous Operations | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Pretax Income | $-115,114,000 | $-103,036,000 | $-110,466,000 | $-105,365,000 |
| Special Income Charges | $5,101,000 | $0 | $-21,335,000 | $0 |
| Operating Income | $-125,418,000 | $-108,888,000 | $-94,180,000 | $-106,750,000 |
| Depreciation Amortization Depletion Income Statement | $11,742,000 | $13,389,000 | $13,999,000 | $13,037,000 |
| Depreciation And Amortization In Income Statement | $11,742,000 | $13,389,000 | $13,999,000 | $13,037,000 |
| Per Share | ||||
| Diluted EPS | $-0.84 | $-0.94 | $-1.20 | $-1.15 |
| Basic EPS | $-0.84 | $-0.94 | $-1.20 | $-1.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,071,210 | $0 | $-4,480,350 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-108,264,000 | $-89,082,000 | $-74,122,000 | $-91,293,000 |
| Total Unusual Items | $5,101,000 | $0 | $-21,335,000 | $0 |
| Total Unusual Items Excluding Goodwill | $5,101,000 | $0 | $-21,335,000 | $0 |
| Reconciled Depreciation | $11,742,000 | $13,389,000 | $13,999,000 | $13,100,000 |
| EBITDA (Bullshit earnings) | $-103,163,000 | $-89,082,000 | $-95,457,000 | $-91,293,000 |
| EBIT | $-114,905,000 | $-102,471,000 | $-109,456,000 | $-104,393,000 |
| Diluted Average Shares | $136,776,885 | $110,239,870 | $92,028,016 | $90,845,629 |
| Basic Average Shares | $136,776,885 | $110,239,870 | $92,028,016 | $90,845,629 |
| Diluted NI Availto Com Stockholders | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Tax Provision | $69,000 | $70,000 | $100,000 | $-461,000 |
| Restructuring And Mergern Acquisition | $-5,101,000 | $0 | - | - |
| Research And Development | $81,418,000 | $63,859,000 | $48,067,000 | $58,908,000 |
| Selling General And Administration | $35,058,000 | $36,174,000 | $37,832,000 | $40,552,000 |
| Impairment Of Capital Assets | - | $0 | $21,335,000 | $0 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $147,935,000 | $134,250,000 | $127,923,000 | $201,457,000 |
| Total Assets | $216,297,000 | $213,608,000 | $217,298,000 | $321,008,000 |
| Total Non Current Assets | $66,724,000 | $79,777,000 | $96,720,000 | $134,145,000 |
| Other Non Current Assets | $1,436,000 | $1,759,000 | $2,649,000 | $3,146,000 |
| Goodwill And Other Intangible Assets | $41,514,000 | $44,883,000 | $48,253,000 | $72,957,000 |
| Other Intangible Assets | $41,514,000 | $44,883,000 | $48,253,000 | $51,622,000 |
| Current Assets | $149,573,000 | $133,831,000 | $120,578,000 | $186,863,000 |
| Other Current Assets | $5,281,000 | $5,459,000 | $4,537,000 | $5,859,000 |
| Restricted Cash | $0 | $15,947,000 | $16,193,000 | $15,023,000 |
| Cash Cash Equivalents And Short Term Investments | $144,292,000 | $112,425,000 | $97,659,000 | $164,431,000 |
| Cash And Cash Equivalents | $20,025,000 | $41,213,000 | $72,362,000 | $59,955,000 |
| Receivables | - | $0 | $2,189,000 | $1,550,000 |
| Accounts Receivable | - | $0 | $2,189,000 | - |
| Other Receivables | - | - | $2,189,000 | $1,550,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $5,302,000 | $10,027,000 | $15,881,000 | $22,983,000 |
| Long Term Debt And Capital Lease Obligation | $2,624,000 | $5,686,000 | $10,303,000 | $16,051,000 |
| Current Debt And Capital Lease Obligation | $2,678,000 | $4,341,000 | $5,578,000 | $6,932,000 |
| Current Debt | $873,000 | $2,733,000 | $3,258,000 | $2,946,000 |
| Other Current Borrowings | $873,000 | $2,733,000 | $3,258,000 | $2,946,000 |
| Long Term Debt | - | $1,257,000 | $4,660,000 | $7,984,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $26,848,000 | $34,475,000 | $41,122,000 | $46,594,000 |
| Total Non Current Liabilities Net Minority Interest | $4,083,000 | $5,819,000 | $11,564,000 | $16,324,000 |
| Other Non Current Liabilities | $1,023,000 | $133,000 | $295,000 | $35,000 |
| Non Current Deferred Liabilities | $436,000 | $0 | $966,000 | $238,000 |
| Current Liabilities | $22,765,000 | $28,656,000 | $29,558,000 | $30,270,000 |
| Current Deferred Liabilities | $739,000 | $1,116,000 | $3,174,000 | $445,000 |
| Payables And Accrued Expenses | $19,348,000 | $10,449,000 | $8,056,000 | $22,893,000 |
| Payables | $2,756,000 | $2,948,000 | $1,503,000 | $2,412,000 |
| Accounts Payable | $2,756,000 | $2,948,000 | $1,503,000 | $2,412,000 |
| Other Current Liabilities | - | $12,750,000 | $12,750,000 | - |
| Non Current Deferred Taxes Liabilities | - | - | $186,000 | $238,000 |
| Equity | ||||
| Common Stock Equity | $189,449,000 | $179,133,000 | $176,176,000 | $274,414,000 |
| Total Equity Gross Minority Interest | $189,449,000 | $179,133,000 | $176,176,000 | $274,414,000 |
| Stockholders Equity | $189,449,000 | $179,133,000 | $176,176,000 | $274,414,000 |
| Gains Losses Not Affecting Retained Earnings | $591,000 | $-4,000 | $-37,000 | $-120,000 |
| Other Equity Adjustments | $591,000 | $-4,000 | $-37,000 | $-120,000 |
| Retained Earnings | $-624,784,000 | $-509,601,000 | $-406,495,000 | $-295,929,000 |
| Other | ||||
| Ordinary Shares Number | $151,515,079 | $115,362,265 | $93,087,675 | $92,411,103 |
| Share Issued | $151,515,079 | $115,362,265 | $93,087,675 | $92,411,103 |
| Tangible Book Value | $147,935,000 | $134,250,000 | $127,923,000 | $201,457,000 |
| Invested Capital | $190,322,000 | $183,123,000 | $184,094,000 | $285,344,000 |
| Working Capital | $126,808,000 | $105,175,000 | $91,020,000 | $156,593,000 |
| Capital Lease Obligations | $4,429,000 | $6,037,000 | $7,963,000 | $12,053,000 |
| Total Capitalization | $189,449,000 | $180,390,000 | $180,836,000 | $282,398,000 |
| Additional Paid In Capital | $813,627,000 | $688,726,000 | $582,699,000 | $570,454,000 |
| Capital Stock | $15,000 | $12,000 | $9,000 | $9,000 |
| Common Stock | $15,000 | $12,000 | $9,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $436,000 | $0 | $966,000 | $0 |
| Long Term Capital Lease Obligation | $2,624,000 | $4,429,000 | $5,643,000 | $8,067,000 |
| Current Deferred Revenue | $739,000 | $1,116,000 | $3,174,000 | $445,000 |
| Current Capital Lease Obligation | $1,805,000 | $1,608,000 | $2,320,000 | $3,986,000 |
| Current Accrued Expenses | $16,592,000 | $7,501,000 | $6,553,000 | $20,481,000 |
| Net PPE | $23,774,000 | $33,135,000 | $45,818,000 | $58,042,000 |
| Accumulated Depreciation | $-35,519,000 | $-31,569,000 | $-23,991,000 | $-15,203,000 |
| Gross PPE | $59,293,000 | $64,704,000 | $69,809,000 | $73,245,000 |
| Leases | $27,079,000 | $27,057,000 | $27,049,000 | $26,860,000 |
| Other Properties | $28,478,000 | $31,262,000 | $36,588,000 | $39,487,000 |
| Machinery Furniture Equipment | $3,736,000 | $6,385,000 | $6,172,000 | $6,605,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $124,267,000 | $71,212,000 | $25,297,000 | $104,476,000 |
| Goodwill | - | - | $0 | $21,335,000 |
| Construction In Progress | - | - | $0 | $293,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-94,032,000 | $-72,806,000 | $-65,496,000 | $-97,514,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-92,925,000 | $-72,402,000 | $-64,636,000 | $-81,339,000 |
| Cash Flow From Continuing Operating Activities | $-92,925,000 | $-72,402,000 | $-64,636,000 | $-81,276,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,107,000 | $-404,000 | $-860,000 | $-16,175,000 |
| Investing Cash Flow | $-50,160,000 | $-41,577,000 | $81,944,000 | $-126,982,000 |
| Cash Flow From Continuing Investing Activities | $-50,160,000 | $-41,577,000 | $81,944,000 | $-126,982,000 |
| Net Other Investing Changes | - | - | - | $650,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $105,835,000 | $82,398,000 | $862,000 | $656,000 |
| Financing Cash Flow | $105,949,000 | $82,526,000 | $-4,483,000 | $5,237,000 |
| Cash Flow From Continuing Financing Activities | $105,949,000 | $82,526,000 | $-4,483,000 | $5,237,000 |
| Net Common Stock Issuance | $105,835,000 | $82,398,000 | $862,000 | $656,000 |
| Common Stock Issuance | $105,835,000 | $82,398,000 | $862,000 | $656,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-3,196,000 | $-4,031,000 | $-5,345,000 | $-7,450,000 |
| Interest Paid Supplemental Data | $178,000 | $561,000 | $970,000 | $895,000 |
| End Cash Position | $21,078,000 | $58,214,000 | $89,667,000 | $76,842,000 |
| Beginning Cash Position | $58,214,000 | $89,667,000 | $76,842,000 | $279,926,000 |
| Changes In Cash | $-37,136,000 | $-31,453,000 | $12,825,000 | $-203,084,000 |
| Proceeds From Stock Option Exercised | $3,310,000 | $4,159,000 | - | - |
| Net Issuance Payments Of Debt | $-3,196,000 | $-4,031,000 | $-5,345,000 | $4,581,000 |
| Net Long Term Debt Issuance | $-3,196,000 | $-4,031,000 | $-5,345,000 | $4,581,000 |
| Long Term Debt Payments | $-3,196,000 | $-4,031,000 | $-5,345,000 | $-7,450,000 |
| Net Investment Purchase And Sale | $-50,365,000 | $-42,112,000 | $82,550,000 | $-103,590,000 |
| Sale Of Investment | $69,501,000 | $144,000,000 | $229,897,000 | $5,000,000 |
| Purchase Of Investment | $-119,866,000 | $-186,112,000 | $-147,347,000 | $-108,590,000 |
| Net PPE Purchase And Sale | $205,000 | $535,000 | $-606,000 | $-16,042,000 |
| Sale Of PPE | $1,312,000 | $939,000 | $254,000 | $133,000 |
| Purchase Of PPE | $-1,107,000 | $-404,000 | $-860,000 | $-16,175,000 |
| Change In Working Capital | $423,000 | $-368,000 | $1,517,000 | $-1,540,000 |
| Change In Other Working Capital | $-496,000 | $-3,786,000 | $2,839,000 | $-1,547,000 |
| Change In Other Current Assets | $249,000 | $-68,000 | $-255,000 | $13,000 |
| Change In Payables And Accrued Expense | $1,094,000 | $1,731,000 | $-1,999,000 | $-2,240,000 |
| Change In Prepaid Assets | $-424,000 | $-484,000 | $1,598,000 | $2,382,000 |
| Change In Receivables | $0 | $2,239,000 | $-666,000 | $-148,000 |
| Changes In Account Receivables | $0 | $2,239,000 | $-666,000 | - |
| Other Non Cash Items | $-5,685,000 | $1,974,000 | $334,000 | $658,000 |
| Stock Based Compensation | $18,321,000 | $19,452,000 | $11,416,000 | $12,540,000 |
| Amortization Of Securities | $-2,543,000 | $-3,743,000 | $-2,671,000 | $-688,000 |
| Depreciation Amortization Depletion | $11,742,000 | $13,389,000 | $13,999,000 | $13,100,000 |
| Depreciation And Amortization | $11,742,000 | $13,389,000 | $13,999,000 | $13,100,000 |
| Net Income From Continuing Operations | $-115,183,000 | $-103,106,000 | $-110,566,000 | $-104,904,000 |
| Change In Accrued Expense | - | $-295,000 | $-1,213,000 | $-1,707,000 |
| Change In Payable | - | $2,026,000 | $-786,000 | $-533,000 |
| Change In Account Payable | - | $2,026,000 | $-786,000 | $-533,000 |
| Asset Impairment Charge | - | $0 | $21,335,000 | $0 |
| Issuance Of Debt | - | - | $0 | $12,031,000 |
| Long Term Debt Issuance | - | - | $0 | $12,031,000 |
| Net Business Purchase And Sale | - | - | $0 | $-8,000,000 |
| Purchase Of Business | - | - | $0 | $-8,000,000 |
| Deferred Tax | - | - | $-52,000 | $-505,000 |
| Deferred Income Tax | - | - | $-52,000 | $-505,000 |
| Amortization Cash Flow | - | - | $3,400,000 | $3,400,000 |
| Amortization Of Intangibles | - | - | $3,400,000 | $3,400,000 |
| Depreciation | - | - | $10,600,000 | $9,700,000 |
| Gain Loss On Investment Securities | - | - | - | - |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-23